Get the Stockscreener App
35.16
18.58%
5.51
Pre-market:
34.50
-0.66
-1.88%
Travere Therapeutics Inc stock is traded at $35.16, with a volume of 6.25M.
It is up +18.58% in the last 24 hours and up +47.11% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$29.65
Open:
$34.6
24h Volume:
6.25M
Relative Volume:
2.90
Market Cap:
$3.13B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-17.24
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
+25.30%
1M Performance:
+47.11%
6M Performance:
+68.96%
1Y Performance:
+100.91%
1-Day Range:
$32.11
$35.34
1-Week Range:
$28.35
$35.34
52-Week Range:
$12.91
$35.34
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
35.16 | 2.64B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Results: Travere Therapeutics, Inc. Exceeded Expectations And The Consensus Lifted Next Year's Outlook - Yahoo Finance
Does Travere Therapeutics Inc. show high probability of rebound2025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Can Travere Therapeutics Inc. stock hit analyst price targetsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Can Travere Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Update Report & Weekly Breakout Opportunity Watchlist - newser.com
Cantor Fitzgerald Issues Negative Estimate for TVTX Earnings - MarketBeat
Will Travere Therapeutics Inc. stock outperform international peersEarnings Growth Summary & Weekly Hot Stock Watchlists - newser.com
Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings - Insider Monkey
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
Will Travere Therapeutics Inc. stock gain from strong economyQuarterly Earnings Summary & Fast Momentum Entry Tips - newser.com
What indicators show strength in Travere Therapeutics Inc.July 2025 Institutional & Long-Term Investment Growth Plans - newser.com
When is the best time to exit Travere Therapeutics Inc.CEO Change & Free High Return Stock Watch Alerts - newser.com
Travere Therapeutics Stock (TVTX) Opinions on Q3 Earnings Surge - Quiver Quantitative
How geopolitical tensions affect Travere Therapeutics Inc. stockJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - newser.com
Jennison Associates LLC Sells 80,602 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Pattern recognition hints at Travere Therapeutics Inc. upsideQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
10 Stocks With Easy 20-40% Gains - Insider Monkey
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2025 Earnings Call Transcript - Insider Monkey
TD Cowen Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Why Travere Therapeutics Inc. stock could outperform in 2025Market Trend Report & Reliable Price Breakout Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
A Look at Travere Therapeutics's Valuation Following Strong Q3 Profit and FILSPARI Momentum - Yahoo Finance
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High Following Earnings Beat - MarketBeat
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone - Yahoo Finance
Travere Therapeutics stock hits 52-week high at 33.66 USD By Investing.com - Investing.com Australia
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives - Yahoo Finance
TD Cowen Raises Price Target for Travere Therapeutics (TVTX) to $40 | TVTX Stock News - GuruFocus
Travere Therapeutics’ Strong Quarter and Future Prospects - TipRanks
Eric Dube Sells 92,872 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $79,860.00 in Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells 27,128 Shares of Stock - MarketBeat
Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M - MSN
Travere Therapeutics (NASDAQ:TVTX) Releases Quarterly Earnings Results, Beats Estimates By $0.59 EPS - MarketBeat
Travere Therapeutics stock hits 52-week high at 33.66 USD - Investing.com
Travere Therapeutics (TVTX) Sees Increased Price Target and Posi - GuruFocus
Top 2% Biotech Screams Up A Beat On Its Linchpin Drug - Investor's Business Daily
Emerald Mutual Fund Advisers Trust Has $16.89 Million Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Backtesting results for Travere Therapeutics Inc. trading strategiesMarket Movement Recap & Safe Entry Momentum Tips - newser.com
Travere therapeutics CEO Dube sells $3.6m in TVTX stock By Investing.com - Investing.com Canada
Can Travere Therapeutics Inc. stock maintain growth trajectoryRisk Management & Weekly Setup with ROI Potential - newser.com
Travere Therapeutics (TVTX) Exceeds Q3 Revenue Expectations, Eyes Future Growth - GuruFocus
Travere Therapeutics Swings to Q3 Non-GAAP Profit, Revenue Rises - MarketScreener
Analyzing drawdowns of Travere Therapeutics Inc. with statistical toolsWeekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com
What momentum shifts mean for Travere Therapeutics Inc.July 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Is Travere Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):